Comparative Pharmacology
Head-to-head clinical analysis: CARTROL versus METOPROLOL TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARTROL versus METOPROLOL TARTRATE.
CARTROL vs METOPROLOL TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARTROL is a beta-1 selective adrenergic receptor antagonist. It inhibits the effects of catecholamines on beta-1 receptors in the heart, reducing heart rate, myocardial contractility, and blood pressure.
Competitive beta-1 adrenergic receptor antagonist with weak beta-2 blocking activity; reduces heart rate, contractility, and AV conduction.
Adults: 2.5 mg orally twice daily, titrated up to maximum 10 mg twice daily.
Initial dose 100 mg daily in divided doses (e.g., 50 mg twice daily) orally; may increase weekly up to 200-450 mg daily in 2-3 divided doses.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <30 mL/min).
3–4 hours (terminal) in healthy adults; prolonged to 7–8 hours in severe hepatic impairment; no change in renal impairment.
Primarily renal excretion (approx. 70% unchanged drug), with 20% biliary/fecal, and 10% metabolism to inactive metabolites.
Renal: 95% as metabolites, <5% unchanged. Fecal: negligible.
Category C
Category C
Beta-Blocker
Beta-Blocker